

Jeremy D Goldhaber-Fiebert

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4314498/publications.pdf>

Version: 2024-02-01

131
papers

5,206
citations

76326

40
h-index

98798

67
g-index

142
all docs

142
docs citations

142
times ranked

7446
citing authors

#	ARTICLE	IF	CITATIONS
1	Assessing Interventions That Prevent Multiple Infectious Diseases: Simple Methods for Multidisease Modeling. <i>Medical Decision Making</i> , 2022, 42, 436-449.	2.4	1
2	Simulating Study Data to Support Expected Value of Sample Information Calculations: A Tutorial. <i>Medical Decision Making</i> , 2022, 42, 143-155.	2.4	6
3	Optimal patient selection for simultaneous heart-kidney transplant: A modified cost-effectiveness analysis. <i>American Journal of Transplantation</i> , 2022, 22, 1158-1168.	4.7	7
4	Perks and Pitfalls of Performance-Linked Reimbursement for Novel Drugs: The Case of Sacubitril-Valsartan. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2022, 15, e007993.	2.2	1
5	Effectiveness of Coronavirus Disease 2019 (COVID-19) Vaccines Among Incarcerated People in California State Prisons: Retrospective Cohort Study. <i>Clinical Infectious Diseases</i> , 2022, 75, e838-e845.	5.8	16
6	Association of Emergency Department Pediatric Readiness With Mortality to 1 Year Among Injured Children Treated at Trauma Centers. <i>JAMA Surgery</i> , 2022, 157, e217419.	4.3	23
7	Cost-Effectiveness of Dapagliflozin for Non-diabetic Chronic Kidney Disease. <i>Journal of General Internal Medicine</i> , 2022, 37, 3380-3387.	2.6	15
8	Cost-Effectiveness Analysis and Microsimulation of Serial Multiparametric Magnetic Resonance Imaging in Active Surveillance of Localized Prostate Cancer. <i>Journal of Urology</i> , 2022, 208, 80-89.	0.4	1
9	Uptake of COVID-19 Vaccination Among Frontline Workers in California State Prisons. <i>JAMA Health Forum</i> , 2022, 3, e220099.	2.2	13
10	RCT of the effectiveness of stepped-care sleep therapy in general practice: The RESTING study protocol. <i>Contemporary Clinical Trials</i> , 2022, 116, 106749.	1.8	9
11	Author Response to "Optimal Sample Size Calculation for Clinical Research under a Budget Constraint". <i>Medical Decision Making</i> , 2022, 42, 419-420.	2.4	0
12	The Household Secondary Attack Rate of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): A Rapid Review. <i>Clinical Infectious Diseases</i> , 2021, 73, S138-S145.	5.8	82
13	How simulation modeling can support the public health response to the opioid crisis in North America: Setting priorities and assessing value. <i>International Journal of Drug Policy</i> , 2021, 88, 102726.	3.3	5
14	Religion and Sanitation Practices. <i>World Bank Economic Review</i> , 2021, 35, 287-302.	2.4	5
15	Comparison of Strategies for Typhoid Conjugate Vaccine Introduction in India: A Cost-Effectiveness Modeling Study. <i>Journal of Infectious Diseases</i> , 2021, 224, S612-S624.	4.0	9
16	Biomedical Decision Making: Probabilistic Clinical Reasoning. , 2021, , 77-120.		0
17	Mapping Inequality in SARS-CoV-2 Household Exposure and Transmission Risk in the USA. <i>Journal of General Internal Medicine</i> , 2021, 36, 1476-1478.	2.6	3
18	Using RE-AIM to examine the potential public health impact of an integrated collaborative care intervention for weight and depression management in primary care: Results from the RAINBOW trial. <i>PLoS ONE</i> , 2021, 16, e0248339.	2.5	5

#	ARTICLE	IF	CITATIONS
19	Patterns of heavy drinking behaviour over age and birth cohorts among Chinese men: a Markov model. <i>BMJ Open</i> , 2021, 11, e043261.	1.9	2
20	Critical Appraisal of Systematic Reviews With Costs and Cost-Effectiveness Outcomes: An ISPOR Good Practices Task Force Report. <i>Value in Health</i> , 2021, 24, 463-472.	0.3	52
21	Predicting the Effectiveness of Endemic Infectious Disease Control Interventions: The Impact of Mass Action versus Network Model Structure. <i>Medical Decision Making</i> , 2021, 41, 623-640.	2.4	2
22	Covid-19 Vaccine Acceptance in California State Prisons. <i>New England Journal of Medicine</i> , 2021, 385, 374-376.	27.0	37
23	Modeling the Cost-Effectiveness of Interventions to Prevent Plague in Madagascar. <i>Tropical Medicine and Infectious Disease</i> , 2021, 6, 101.	2.3	6
24	Racial/Ethnic Disparities In COVID-19 Exposure Risk, Testing, And Cases At The Subcounty Level In California. <i>Health Affairs</i> , 2021, 40, 870-878.	5.2	102
25	Impact of treatment duration on mortality among Veterans with opioid use disorder in the United States Veterans Health Administration. <i>Addiction</i> , 2021, 116, 3494-3503.	3.3	8
26	Availability of Cost-effectiveness Studies for Drugs With High Medicare Part D Expenditures. <i>JAMA Network Open</i> , 2021, 4, e2113969.	5.9	2
27	COVID-19 in the California State Prison System: an Observational Study of Decarceration, Ongoing Risks, and Risk Factors. <i>Journal of General Internal Medicine</i> , 2021, 36, 3096-3102.	2.6	37
28	Cost-effectiveness of Treatments for Opioid Use Disorder. <i>JAMA Psychiatry</i> , 2021, 78, 767.	11.0	45
29	Cost-effectiveness of Dapagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2021, 6, 926.	6.1	65
30	Health Disparities And COVID-19: The Authors Reply. <i>Health Affairs</i> , 2021, 40, 1514-1514.	5.2	0
31	Evaluation of Emergency Department Pediatric Readiness and Outcomes Among US Trauma Centers. <i>JAMA Pediatrics</i> , 2021, 175, 947.	6.2	40
32	Outbreaks of COVID-19 variants in US prisons: a mathematical modelling analysis of vaccination and reopening policies. <i>Lancet Public Health</i> , The, 2021, 6, e760-e770.	10.0	35
33	Nationwide cost-effectiveness analysis of surgical stabilization of rib fractures by flail chest status and age groups. <i>Journal of Trauma and Acute Care Surgery</i> , 2021, 90, 451-458.	2.1	16
34	Dependence of COVID-19 Policies on End-of-Year Holiday Contacts in Mexico City Metropolitan Area: A Modeling Study. <i>MDM Policy and Practice</i> , 2021, 6, 238146832110492.	0.9	2
35	Effectiveness of the mRNA-1273 Vaccine during a SARS-CoV-2 Delta Outbreak in a Prison. <i>New England Journal of Medicine</i> , 2021, 385, 2300-2301.	27.0	31
36	Quantifying and Benchmarking Disparities in COVID-19 Vaccination Rates by Race and Ethnicity. <i>JAMA Network Open</i> , 2021, 4, e2130343.	5.9	39

#	ARTICLE	IF	CITATIONS
37	Prevention and control of dengue and chikungunya in Colombia: A cost-effectiveness analysis. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0010086.	3.0	3
38	Cost-effectiveness of a Pharmacogenomic Test for Stratified Isoniazid Dosing in Treatment of Active Tuberculosis. <i>Clinical Infectious Diseases</i> , 2020, 71, 3136-3143.	5.8	17
39	Defining a Willingness-to-transplant Threshold in an Era of Organ Scarcity: Simultaneous Liver-€ kidney Transplant as a Case Example. <i>Transplantation</i> , 2020, 104, 387-394.	1.0	13
40	Optimal Allocation of Research Funds under a Budget Constraint. <i>Medical Decision Making</i> , 2020, 40, 797-814.	2.4	2
41	Methods for Model Calibration under High Uncertainty: Modeling Cholera in Bangladesh. <i>Medical Decision Making</i> , 2020, 40, 693-709.	2.4	7
42	Cost-Effectiveness of Transitional Care Services After Hospitalization With Heart Failure. <i>Annals of Internal Medicine</i> , 2020, 172, 248.	3.9	30
43	What Is the Optimal Primary Care Panel Size?. <i>Annals of Internal Medicine</i> , 2020, 172, 195.	3.9	15
44	Public Health Interventions with Harms and Benefits: A Graphical Framework for Evaluating Tradeoffs. <i>Medical Decision Making</i> , 2020, 40, 978-989.	2.4	1
45	First-€ Year Economic and Quality of Life Effects of the RAINBOW Intervention to Treat Comorbid Obesity and Depression. <i>Obesity</i> , 2020, 28, 1031-1039.	3.0	5
46	Computing the Expected Value of Sample Information Efficiently: Practical Guidance and Recommendations for Four Model-Based Methods. <i>Value in Health</i> , 2020, 23, 734-742.	0.3	51
47	Effect of an Intervention for Obesity and Depression on Patient-Centered Outcomes: An RCT. <i>American Journal of Preventive Medicine</i> , 2020, 58, 496-505.	3.0	9
48	Calculating the Expected Value of Sample Information in Practice: Considerations from 3 Case Studies. <i>Medical Decision Making</i> , 2020, 40, 314-326.	2.4	28
49	School Reopenings and the Community During the COVID-19 Pandemic. <i>JAMA Health Forum</i> , 2020, 1, e201294.	2.2	11
50	Cost-Effectiveness of Initial Versus Delayed Lanreotide for Treatment of Metastatic Enteropancreatic Neuroendocrine Tumors. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1200-1209.	4.9	3
51	Quantifying Positive Health Externalities of Disease Control Interventions: Modeling Chikungunya and Dengue. <i>Medical Decision Making</i> , 2019, 39, 1045-1058.	2.4	4
52	Operative Versus Nonoperative Management of Appendicitis: A Long-Term Cost Effectiveness Analysis. <i>MDM Policy and Practice</i> , 2019, 4, 238146831986644.	0.9	6
53	Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 2105-2119.	1.6	155
54	The Costs of Hepatitis C by Liver Disease Stage: Estimates from the Veterans Health Administration. <i>Applied Health Economics and Health Policy</i> , 2019, 17, 513-521.	2.1	2

#	ARTICLE	IF	CITATIONS
55	Building a tuberculosis-free world: The Lancet Commission on tuberculosis. <i>Lancet, The</i> , 2019, 393, 1331-1384.	13.7	257
56	Cost-effectiveness of Screening for Nasopharyngeal Carcinoma among Asian American Men in the United States. <i>Otolaryngology - Head and Neck Surgery</i> , 2019, 161, 82-90.	1.9	8
57	Effect of Integrated Behavioral Weight Loss Treatment and Problem-Solving Therapy on Body Mass Index and Depressive Symptoms Among Patients With Obesity and Depression. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 869.	7.4	90
58	Cost-effectiveness of Canakinumab for Prevention of Recurrent Cardiovascular Events. <i>JAMA Cardiology</i> , 2019, 4, 128.	6.1	61
59	How does information on the harms and benefits of cervical cancer screening alter the intention to be screened?: a randomized survey of Norwegian women. <i>European Journal of Cancer Prevention</i> , 2019, 28, 87-95.	1.3	2
60	Effect of Interferon-Free Regimens on Disparities in Hepatitis C Treatment of US Veterans. <i>Value in Health</i> , 2018, 21, 921-930.	0.3	8
61	Optimal timing of drug sensitivity testing for patients on first-line tuberculosis treatment. <i>Health Care Management Science</i> , 2018, 21, 632-646.	2.6	14
62	Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Pediatric B-Cell Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2018, 36, 3192-3202.	1.6	110
63	Population Health and Cost-Effectiveness Implications of a "Treat All" Recommendation for HCV: A Review of the Model-Based Evidence. <i>MDM Policy and Practice</i> , 2018, 3, 238146831877663.	0.9	26
64	Cost-effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia in older adults without deletion 17p. <i>Blood Advances</i> , 2018, 2, 1946-1956.	5.2	40
65	Optimal Information Collection Policies in a Markov Decision Process Framework. <i>Medical Decision Making</i> , 2018, 38, 797-809.	2.4	3
66	Comparing Simultaneous Liver-Kidney Transplant Strategies. <i>Transplantation</i> , 2018, 102, e219-e228.	1.0	9
67	Economically Efficient Hepatitis C Virus Treatment Prioritization Improves Health Outcomes. <i>Medical Decision Making</i> , 2018, 38, 849-865.	2.4	6
68	Cost-effectiveness of multidisciplinary care in mild to moderate chronic kidney disease in the United States: A modeling study. <i>PLoS Medicine</i> , 2018, 15, e1002532.	8.4	44
69	Optimizing patient treatment decisions in an era of rapid technological advances: the case of hepatitis C treatment. <i>Health Care Management Science</i> , 2017, 20, 16-32.	2.6	14
70	Cost-Effectiveness of Left Ventricular Assist Devices in Ambulatory Patients With Advanced Heart Failure. <i>JACC: Heart Failure</i> , 2017, 5, 110-119.	4.1	97
71	Cost-effectiveness of Intensive Blood Pressure Management—Is There an Additional Price to Pay?—Reply. <i>JAMA Cardiology</i> , 2017, 2, 581.	6.1	0
72	Risk stratification in compartmental epidemic models: Where to draw the line?. <i>Journal of Theoretical Biology</i> , 2017, 428, 1-17.	1.7	5

#	ARTICLE	IF	CITATIONS
73	Cost-effectiveness of Stereotactic Body Radiation Therapy versus Radiofrequency Ablation for Hepatocellular Carcinoma: A Markov Modeling Study. <i>Radiology</i> , 2017, 283, 460-468.	7.3	36
74	Profiles of sociodemographic, behavioral, clinical and psychosocial characteristics among primary care patients with comorbid obesity and depression. <i>Preventive Medicine Reports</i> , 2017, 8, 42-50.	1.8	13
75	Estimation of the cost-effectiveness of HIV prevention portfolios for people who inject drugs in the United States: A model-based analysis. <i>PLoS Medicine</i> , 2017, 14, e1002312.	8.4	53
76	Evaluation of a social franchising and telemedicine programme and the care provided for childhood diarrhoea and pneumonia, Bihar, India. <i>Bulletin of the World Health Organization</i> , 2017, 95, 343-352E.	3.3	27
77	Cost-Effectiveness of Treatments for Genotype 1 Hepatitis C Virus Infection in Non-VA and VA Populations. <i>MDM Policy and Practice</i> , 2016, 1, 238146831667194.	0.9	7
78	Cost-Effectiveness of HIV Preexposure Prophylaxis for People Who Inject Drugs in the United States. <i>Annals of Internal Medicine</i> , 2016, 165, 10.	3.9	45
79	An Efficient, Noniterative Method of Identifying the Cost-Effectiveness Frontier. <i>Medical Decision Making</i> , 2016, 36, 132-136.	2.4	7
80	Feasibility of achieving the 2025 WHO global tuberculosis targets in South Africa, China, and India: a combined analysis of 11 mathematical models. <i>The Lancet Global Health</i> , 2016, 4, e806-e815.	6.3	138
81	Cost-effectiveness and resource implications of aggressive action on tuberculosis in China, India, and South Africa: a combined analysis of nine models. <i>The Lancet Global Health</i> , 2016, 4, e816-e826.	6.3	69
82	Effect Of A Large-Scale Social Franchising And Telemedicine Program On Childhood Diarrhea And Pneumonia Outcomes In India. <i>Health Affairs</i> , 2016, 35, 1800-1809.	5.2	25
83	Cost-effectiveness of Intensive Blood Pressure Management. <i>JAMA Cardiology</i> , 2016, 1, 872.	6.1	48
84	Providers' knowledge of diagnosis and treatment of tuberculosis using vignettes: evidence from rural Bihar, India. <i>BMJ Global Health</i> , 2016, 1, e000155.	4.7	12
85	Some Health States Are Better Than Others. <i>Medical Decision Making</i> , 2016, 36, 927-940.	2.4	18
86	Cost-Effectiveness of Implantable Pulmonary Artery Pressure Monitoring in Chronic Heart Failure. <i>JACC: Heart Failure</i> , 2016, 4, 368-375.	4.1	74
87	Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 902-909.	1.6	99
88	Cost-Effectiveness of Adding Cardiac Resynchronization Therapy to an Implantable Cardioverter-Defibrillator Among Patients With Mild Heart Failure. <i>Annals of Internal Medicine</i> , 2015, 163, 417-426.	3.9	23
89	Quantifying demographic and socioeconomic transitions for computational epidemiology: an open-source modeling approach applied to India. <i>Population Health Metrics</i> , 2015, 13, 19.	2.7	3
90	New, Expensive Treatments for Chronic Hepatitis C: Insuring Good Outcomes?. <i>Digestive Diseases and Sciences</i> , 2015, 60, 3153-3154.	2.3	0

#	ARTICLE	IF	CITATIONS
91	Research aimed at improving both mood and weight (RAINBOW) in primary care: A type 1 hybrid design randomized controlled trial. <i>Contemporary Clinical Trials</i> , 2015, 43, 260-278.	1.8	35
92	Will Divestment from Employment-Based Health Insurance Save Employers Money? The Case of State and Local Governments. <i>Journal of Empirical Legal Studies</i> , 2015, 12, 343-394.	0.8	3
93	Modeling and Calibration for Exposure to Time-Varying, Modifiable Risk Factors. <i>Medical Decision Making</i> , 2015, 35, 196-210.	2.4	6
94	The Know-Do Gap in Quality of Health Care for Childhood Diarrhea and Pneumonia in Rural India. <i>JAMA Pediatrics</i> , 2015, 169, 349.	6.2	141
95	Computing Expected Value of Partial Sample Information from Probabilistic Sensitivity Analysis Using Linear Regression Metamodeling. <i>Medical Decision Making</i> , 2015, 35, 584-595.	2.4	43
96	Disease Control Implications of India's Changing Multi-Drug Resistant Tuberculosis Epidemic. <i>PLoS ONE</i> , 2014, 9, e89822.	2.5	24
97	Tuberculosis treatment discontinuation and symptom persistence: an observational study of Bihar, India's public care system covering >100,000,000 inhabitants. <i>BMC Public Health</i> , 2014, 14, 418.	2.9	24
98	Exploration and adoption of evidence-based practice by US child welfare agencies. <i>Children and Youth Services Review</i> , 2014, 39, 147-152.	1.9	50
99	Explaining variations in state foster care maintenance rates and the implications for implementing new evidence-based programs. <i>Children and Youth Services Review</i> , 2014, 39, 183-206.	1.9	6
100	Sofosbuvir-Based Treatment Regimens for Chronic, Genotype 1 Hepatitis C Virus Infection in U.S. Incarcerated Populations. <i>Annals of Internal Medicine</i> , 2014, 161, 546.	3.9	77
101	Cost-Effectiveness of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease. <i>Annals of Internal Medicine</i> , 2014, 160, 143.	3.9	0
102	Cost-Effectiveness of Statins for Primary Cardiovascular Prevention in Chronic Kidney Disease. <i>Journal of the American College of Cardiology</i> , 2013, 61, 1250-1258.	2.8	47
103	Analyzing Screening Policies for Childhood Obesity. <i>Management Science</i> , 2013, 59, 782-795.	4.1	15
104	Palm oil taxes and cardiovascular disease mortality in India: economic-epidemiologic model. <i>BMJ</i> , The, 2013, 347, f6048-f6048.	6.0	45
105	The Utility of Childhood and Adolescent Obesity Assessment in Relation to Adult Health. <i>Medical Decision Making</i> , 2013, 33, 163-175.	2.4	35
106	Cost-Effectiveness of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease. <i>Annals of Internal Medicine</i> , 2013, 159, 382.	3.9	56
107	Cost-Effectiveness Analysis of Risk-Factor Guided and Birth-Cohort Screening for Chronic Hepatitis C Infection in the United States. <i>PLoS ONE</i> , 2013, 8, e58975.	2.5	61
108	Prioritizing Guideline-Recommended Interventions. <i>Annals of Internal Medicine</i> , 2013, 159, 223.	3.9	10

#	ARTICLE	IF	CITATIONS
109	Screening and Rapid Molecular Diagnosis of Tuberculosis in Prisons in Russia and Eastern Europe: A Cost-Effectiveness Analysis. <i>PLoS Medicine</i> , 2012, 9, e1001348.	8.4	44
110	Diabetes, Its Treatment, and Catastrophic Medical Spending in 35 Developing Countries. <i>Diabetes Care</i> , 2012, 35, 319-326.	8.6	74
111	New Protease Inhibitors for the Treatment of Chronic Hepatitis C. <i>Annals of Internal Medicine</i> , 2012, 156, 279.	3.9	176
112	Assessing Screening Policies for Childhood Obesity. <i>Obesity</i> , 2012, 20, 1437-1443.	3.0	9
113	Evaluating Child Welfare Policies with Decision-Analytic Simulation Models. <i>Administration and Policy in Mental Health and Mental Health Services Research</i> , 2012, 39, 466-477.	2.1	13
114	Economic evaluation research in the context of Child Welfare policy: A structured literature review and recommendations. <i>Child Abuse and Neglect</i> , 2011, 35, 722-740.	2.6	28
115	Multi-Country analysis of palm oil consumption and cardiovascular disease mortality for countries at different stages of economic development: 1980-1997. <i>Globalization and Health</i> , 2011, 7, 45.	4.9	58
116	Diabetes mellitus and tuberculosis in countries with high tuberculosis burdens: individual risks and social determinants. <i>International Journal of Epidemiology</i> , 2011, 40, 417-428.	1.9	105
117	The Business Case for Quality Improvement. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2011, 4, 416-424.	2.2	45
118	Cost Effectiveness of Fibrosis Assessment Prior to Treatment for Chronic Hepatitis C Patients. <i>PLoS ONE</i> , 2011, 6, e26783.	2.5	41
119	Empirically Evaluating Decision-Analytic Models. <i>Value in Health</i> , 2010, 13, 667-674.	0.3	24
120	Quantifying Child Mortality Reductions Related to Measles Vaccination. <i>PLoS ONE</i> , 2010, 5, e13842.	2.5	21
121	Program Spending to Increase Adherence: South African Cervical Cancer Screening. <i>PLoS ONE</i> , 2009, 4, e5691.	2.5	23
122	Cost-Effectiveness of Cervical Cancer Screening With Human Papillomavirus DNA Testing and HPV-16,18 Vaccination. <i>Journal of the National Cancer Institute</i> , 2008, 100, 308-320.	6.3	199
123	Trade-offs in Cervical Cancer Prevention. <i>Archives of Internal Medicine</i> , 2008, 168, 1881.	3.8	52
124	Cost-effectiveness of HPV 16, 18 vaccination in Brazil. <i>Vaccine</i> , 2007, 25, 6257-6270.	3.8	139
125	Modeling human papillomavirus and cervical cancer in the United States for analyses of screening and vaccination. <i>Population Health Metrics</i> , 2007, 5, 11.	2.7	74
126	Chapter 18: Public health policy for cervical cancer prevention: The role of decision science, economic evaluation, and mathematical modeling. <i>Vaccine</i> , 2006, 24, S155-S163.	3.8	64

#	ARTICLE	IF	CITATIONS
127	Estimating the cost of cervical cancer screening in five developing countries. <i>Cost Effectiveness and Resource Allocation</i> , 2006, 4, 13.	1.5	34
128	The costs of reducing loss to follow-up in South African cervical cancer screening. <i>Cost Effectiveness and Resource Allocation</i> , 2005, 3, 11.	1.5	37
129	Cost-Effectiveness of Cervical-Cancer Screening in Five Developing Countries. <i>New England Journal of Medicine</i> , 2005, 353, 2158-2168.	27.0	527
130	Male involvement in cardiovascular preventive healthcare in two rural Costa Rican communities. <i>Preventive Medicine</i> , 2005, 40, 690-695.	3.4	1
131	Randomized Controlled Community-Based Nutrition and Exercise Intervention Improves Glycemia and Cardiovascular Risk Factors in Type 2 Diabetic Patients in Rural Costa Rica. <i>Diabetes Care</i> , 2003, 26, 24-29.	8.6	141